New hope for pancreatic cancer: targeted antibody plus chemotherapy enters phase 3 trial
NCT ID NCT07383922
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding the experimental antibody FG-M108 to standard chemotherapy (gemcitabine and nab-paclitaxel) helps people with advanced pancreatic cancer live longer. About 524 participants with Claudin18.2-positive tumors will be randomly assigned to receive either the antibody or a placebo, plus chemo. The study is not yet recruiting and aims to find a more effective first-line treatment for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FG-M108 (a monoclonal antibody) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If successful, this could provide a new first-line treatment option for advanced pancreatic cancer, potentially extending survival for patients with Claudin18.2-positive tumors.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The drug may not improve survival or could cause additional side effects when combined with chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••